BCAX – bicara therapeutics inc. (US:NASDAQ)
Stock Stats
News
Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement [Seeking Alpha]
Bicara Therapeutics (BCAX) had its price target raised by The Goldman Sachs Group, Inc. from $14.00 to $16.00. They now have a "neutral" rating on the stock.
Bicara Therapeutics (BCAX) had its price target raised by Wells Fargo & Company from $11.00 to $16.00. They now have an "equal weight" rating on the stock.
Bicara Therapeutics (BCAX) had its "outperform" rating reaffirmed by Wedbush. They now have a $30.00 price target on the stock.
Bicara Therapeutics (BCAX) had its "market outperform" rating reaffirmed by Citizens Jmp. They now have a $31.00 price target on the stock.
Form S-8 Bicara Therapeutics Inc.
Form 10-K Bicara Therapeutics Inc. For: Dec 31
Form 8-K Bicara Therapeutics Inc. For: Mar 30
Form 4 Bicara Therapeutics Inc. For: Mar 25 Filed by: Raben David
Form 144 Bicara Therapeutics Inc. Filed by: Raben David
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.